Петр Александрович Белый
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Петр Александрович Белый has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Kira Ya. Zaslavskaya
National Research Ogarev Mordovia State University
33 shared publications - Alexey Viktorovich Taganov
Russian Medical Academy of Continuous Professional Education
14 shared publications - Larisa Aleksandrovna Balykova
N.P. Ogarev Mordovia State University
14 shared publications - Ksenia N. Koryanova
Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University. 2. Russian Medical Academy of Continuing Professional Education
12 shared publications - Dmitrii N. Andreev
Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia
11 shared publications - Igor E. Shokhin
Limited Liability Company "Center of Pharmaceutical Analytics" (LLC "CPHA"); National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
11 shared publications
Latest Publications
- Open Access
Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-Resistant Helicobacter pylori: A Systematic Review and Meta-Analysis
Background: Clarithromycin resistance represents the primary obstacle to the success of conventional proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (H. pylori) eradication. Potassium-competitive acid blockers (P-CABs) offer faster and more potent acid suppression, which may enhance the efficacy of eradication regimens in this resistant population. The present study aimed to systematically evaluate the comparative efficacy of P-CAB-based versus PPI-based eradication regimens specifically in adult patients with documented clarithromycin-resistant H. pylori infection. Methods: This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines. The protocol was prospectively registered in PROSPERO (CRD420261407870). A systematic literature search was performed in Embase; MEDLINE/PubMed; CENTRAL; and Web of Science for articles published from 1 February 2015 to 31 March 2026. The included evidence comprised randomized and non-randomized comparative studies, as well as non-comparative studies. The primary outcome was the H. pylori eradication rate. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model (DerSimonian–Laird method). Risk of bias was assessed using RoB 2 for randomized comparative studies, ROBINS-I for non-randomized comparative studies, and the JBI Critical Appraisal Checklist for Case Series for non-comparative studies. Results: A total of 20 unique publications were included; 12 contributed data to the comparative analysis and 9 contributed data to the non-comparative single-arm analysis, with one publication contributing to both analyses. Across the 12 comparative studies, successful eradication was achieved in 464 of 621 patients (74.7%) receiving P-CAB-based regimens and in 301 of 571 patients (52.7%) receiving PPI-based comparators. P-CAB-based regimens were associated with a significantly higher probability of successful eradication compared with PPIs (RR, 1.42; 95% CI, 1.14–1.76; p < 0.00001). Subgroup analysis according to the P-CAB agent demonstrated that vonoprazan-based regimens exhibited the strongest comparative effect (RR, 1.78; 95% CI, 1.55–2.04), while tegoprazan-based regimens also remained superior (RR, 1.26; 95% CI, 1.04–1.54). The benefit of P-CABs was most pronounced in the clarithromycin-containing triple therapy subgroup (RR, 1.79; 95% CI, 1.55–2.07). Conclusions: P-CAB-based eradication regimens are significantly more effective than PPI-based comparators in patients with clarithromycin-resistant H. pylori infection. Further well-designed studies are warranted to determine the optimal antibiotic combinations, treatment durations, and regional applicability of these regimens.
Open AccessEfficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-Resistant Helicobacter pylori: A Systematic Review and Meta-Analysis
Background: Clarithromycin resistance represents the primary obstacle to the success of conventional proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (H. pylori) eradication. Potassium-competitive acid blockers (P-CABs) offer faster and more potent acid suppression, which may enhance the efficacy of eradication regimens in this resistant population. The present study aimed to systematically evaluate the comparative efficacy of P-CAB-based versus PPI-based eradication regimens specifically in adult patients with documented clarithromycin-resistant H. pylori infection. Methods: This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines. The protocol was prospectively registered in PROSPERO (CRD420261407870). A systematic literature search was performed in Embase; MEDLINE/PubMed; CENTRAL; and Web of Science for articles published from 1 February 2015 to 31 March 2026. The included evidence comprised randomized and non-randomized comparative studies, as well as non-comparative studies. The primary outcome was the H. pylori eradication rate. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model (DerSimonian–Laird method). Risk of bias was assessed using RoB 2 for randomized comparative studies, ROBINS-I for non-randomized comparative studies, and the JBI Critical Appraisal Checklist for Case Series for non-comparative studies. Results: A total of 20 unique publications were included; 12 contributed data to the comparative analysis and 9 contributed data to the non-comparative single-arm analysis, with one publication contributing to both analyses. Across the 12 comparative studies, successful eradication was achieved in 464 of 621 patients (74.7%) receiving P-CAB-based regimens and in 301 of 571 patients (52.7%) receiving PPI-based comparators. P-CAB-based regimens were associated with a significantly higher probability of successful eradication compared with PPIs (RR, 1.42; 95% CI, 1.14–1.76; p < 0.00001). Subgroup analysis according to the P-CAB agent demonstrated that vonoprazan-based regimens exhibited the strongest comparative effect (RR, 1.78; 95% CI, 1.55–2.04), while tegoprazan-based regimens also remained superior (RR, 1.26; 95% CI, 1.04–1.54). The benefit of P-CABs was most pronounced in the clarithromycin-containing triple therapy subgroup (RR, 1.79; 95% CI, 1.55–2.07). Conclusions: P-CAB-based eradication regimens are significantly more effective than PPI-based comparators in patients with clarithromycin-resistant H. pylori infection. Further well-designed studies are warranted to determine the optimal antibiotic combinations, treatment durations, and regional applicability of these regimens.
- Open Access
- 20 July 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (4) , 387-409
Comparative analysis of bioequivalence, safety, and tolerability of semaglutide (tablets): results of an open-label randomized crossover comparative study
The aim. To conduct a comparative evaluation of the physicochemical properties, biological activity, bioequivalence, and safety, including tolerability and immunogenicity, of the drug Semaltara® (semaglutide, tablets 3 and 14 mg (Biochemik, Russia) and the drug Rebelas® (semaglutide, tablets in dosages of 3 and 14 mg (Novo Nordisk A/S, Denmark) when administered to healthy volunteers. Materials and Methods. To assess the bioequivalence of the investigational drug Semaltara® (semaglutide, tablets 3 and 14 mg (Biochemik, Russia) with a chemically synthesized active substance to the original (reference) drug Rebelas® (semaglutide, tablets in dosages of 3 and 14 mg (Novo Nordisk A/S, Denmark), an open-label randomized crossover comparative study ( n = 110) was conducted. Patients were randomized into 4 groups: Group 1 ( n = 25) — patients received the investigational drug Semaltara® and the comparator drug Rebelas® daily once a day at a dose of 3 mg (1 tablet) for 28 days; Group 2 ( n = 25) — the comparator drug Rebelas® and the investigational drug Semaltara® daily once a day at a dose of 3 mg (1 tablet) for 28 days; Group 3 ( n = 30) — the investigational drug Semaltara® and the comparator drug Rebelas® daily once a day at a dose of 14 mg (1 tablet) for 28 days; Group 4 ( n = 30) — the comparator drug Rebelas® and the investigational drug Semaltara® daily once a day at a dose of 14 mg (1 tablet) for 28 days. The concentration of semaglutide was determined in serum samples using a pre-validated enzyme-linked immunosorbent assay (ELISA) method. The conclusion on bioequivalence of the compared drugs was made based on the assessment of 90 % confidence intervals for the ratios of geometric mean values of C max and AUC (0–t) parameters of semaglutide in the original units of measurement. Results. The results of the clinical study demonstrated the bioequivalence of the investigational drug and the comparator drug. The pharmacokinetic parameters of the drugs were comparable: Based on statistical analysis, the obtained 90 % confidence intervals for the ratio of C max,ss and AUC (0- τ )ss values of semaglutide 3 mg were 96.57–120.94 % and 94.37–120.06 %, respectively. For the 14 mg dosage, the 90 % confidence intervals for the ratio of C max,ss and AUC (0- τ )ss values of semaglutide were 91.79–109.68 % and 91.47–112.80 %, respectively. The tolerability of the drugs in volunteers was noted as good. No serious adverse events were registered during the entire study. Thus, the investigational drug Semaltara®, tablets, and the comparator drug Rebelas®, tablets, have a similar safety profile, including tolerability, at both the 3 mg and 14 mg dosages. Conclusion . The conducted study demonstrated the bioequivalence and similar safety profile, as well as tolerability of the Russian drug Semaltara® (semaglutide 3 and 14 mg, tablets, Promomed LLC, Russia) in comparison with the foreign drug Rebelas® (semaglutide, tablets in dosages of 3 and 14 mg (Novo Nordisk A/S, Denmark).
- 20 July 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (4) , 387-409
Open AccessComparative analysis of bioequivalence, safety, and tolerability of semaglutide (tablets): results of an open-label randomized crossover comparative study
The aim. To conduct a comparative evaluation of the physicochemical properties, biological activity, bioequivalence, and safety, including tolerability and immunogenicity, of the drug Semaltara® (semaglutide, tablets 3 and 14 mg (Biochemik, Russia) and the drug Rebelas® (semaglutide, tablets in dosages of 3 and 14 mg (Novo Nordisk A/S, Denmark) when administered to healthy volunteers. Materials and Methods. To assess the bioequivalence of the investigational drug Semaltara® (semaglutide, tablets 3 and 14 mg (Biochemik, Russia) with a chemically synthesized active substance to the original (reference) drug Rebelas® (semaglutide, tablets in dosages of 3 and 14 mg (Novo Nordisk A/S, Denmark), an open-label randomized crossover comparative study ( n = 110) was conducted. Patients were randomized into 4 groups: Group 1 ( n = 25) — patients received the investigational drug Semaltara® and the comparator drug Rebelas® daily once a day at a dose of 3 mg (1 tablet) for 28 days; Group 2 ( n = 25) — the comparator drug Rebelas® and the investigational drug Semaltara® daily once a day at a dose of 3 mg (1 tablet) for 28 days; Group 3 ( n = 30) — the investigational drug Semaltara® and the comparator drug Rebelas® daily once a day at a dose of 14 mg (1 tablet) for 28 days; Group 4 ( n = 30) — the comparator drug Rebelas® and the investigational drug Semaltara® daily once a day at a dose of 14 mg (1 tablet) for 28 days. The concentration of semaglutide was determined in serum samples using a pre-validated enzyme-linked immunosorbent assay (ELISA) method. The conclusion on bioequivalence of the compared drugs was made based on the assessment of 90 % confidence intervals for the ratios of geometric mean values of C max and AUC (0–t) parameters of semaglutide in the original units of measurement. Results. The results of the clinical study demonstrated the bioequivalence of the investigational drug and the comparator drug. The pharmacokinetic parameters of the drugs were comparable: Based on statistical analysis, the obtained 90 % confidence intervals for the ratio of C max,ss and AUC (0- τ )ss values of semaglutide 3 mg were 96.57–120.94 % and 94.37–120.06 %, respectively. For the 14 mg dosage, the 90 % confidence intervals for the ratio of C max,ss and AUC (0- τ )ss values of semaglutide were 91.79–109.68 % and 91.47–112.80 %, respectively. The tolerability of the drugs in volunteers was noted as good. No serious adverse events were registered during the entire study. Thus, the investigational drug Semaltara®, tablets, and the comparator drug Rebelas®, tablets, have a similar safety profile, including tolerability, at both the 3 mg and 14 mg dosages. Conclusion . The conducted study demonstrated the bioequivalence and similar safety profile, as well as tolerability of the Russian drug Semaltara® (semaglutide 3 and 14 mg, tablets, Promomed LLC, Russia) in comparison with the foreign drug Rebelas® (semaglutide, tablets in dosages of 3 and 14 mg (Novo Nordisk A/S, Denmark).
- Open Access
- 20 July 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (4) , 410-422
Evaluation of the effect of semaglutide on certain cardiovascular risk factors in overweight or obese healthcare workers. The “Start with yourself” program: a post-registration, single-center, prospective study of routine clinical practice
The aim . To evaluate the effect of semaglutide on certain cardiovascular risk factors in patients with obesity. Materials and methods. The study included 50 individuals: men and women aged 18 to 65 years, patients with overweight (BMI ≥ 27 and < 30) and obesity (BMI ≥ 30), combined with at least one comorbidity (prediabetes or type 2 diabetes mellitus), arterial hypertension, dyslipidemia, obstructive sleep apnea syndrome, or cardiovascular disease. Patients received subcutaneous semaglutide (Velgia®) once a week. Clinical examination was performed, including: interview, blood pressure measurement, anthropometric data assessment (height, weight, BMI, waist circumference, and hip circumference), cardiovascular risk assessment using the SCORE scale, biochemical blood analysis (including lipid profile), and adverse event registration. Results. A significant decrease in body weight, BMI, waist circumference, and hip circumference was observed after 12 weeks of semaglutide therapy. By 24 weeks, a sustained reduction in these indicators continued. After 6 months of semaglutide use, positive changes in the lipid profile were identified: a decrease in total cholesterol by 8.27% due to a decrease in non-HDL cholesterol, LDL cholesterol by 12.73 %, triglycerides by 13.09 %, and the atherogenic index by 1.83 %. Velgia® therapy for 6 months led to a reduction in the calculated 10-year cardiovascular risk according to the SCORE2 scale by 18.6 %. Analysis of anthropometric and biochemical blood data showed a significant decrease in indicators, indicating a reduced risk of cardiovascular events in patients with obesity. Conclusion. During semaglutide therapy, no clinically significant changes were observed in liver function parameters (ALT, AST, ALP, bilirubin), pancreas (amylase), kidneys (creatinine, urea, GFR), and systemic inflammation markers (CRP). However, a significant decrease in transaminase activity (ALT, AST) and blood uric acid concentration was noted. The registered adverse events (primarily gastrointestinal: nausea, epigastric discomfort) were temporary and moderate in nature. No cardiovascular events were observed during the use of semaglutide.
- 20 July 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (4) , 410-422
Open AccessEvaluation of the effect of semaglutide on certain cardiovascular risk factors in overweight or obese healthcare workers. The “Start with yourself” program: a post-registration, single-center, prospective study of routine clinical practice
The aim . To evaluate the effect of semaglutide on certain cardiovascular risk factors in patients with obesity. Materials and methods. The study included 50 individuals: men and women aged 18 to 65 years, patients with overweight (BMI ≥ 27 and < 30) and obesity (BMI ≥ 30), combined with at least one comorbidity (prediabetes or type 2 diabetes mellitus), arterial hypertension, dyslipidemia, obstructive sleep apnea syndrome, or cardiovascular disease. Patients received subcutaneous semaglutide (Velgia®) once a week. Clinical examination was performed, including: interview, blood pressure measurement, anthropometric data assessment (height, weight, BMI, waist circumference, and hip circumference), cardiovascular risk assessment using the SCORE scale, biochemical blood analysis (including lipid profile), and adverse event registration. Results. A significant decrease in body weight, BMI, waist circumference, and hip circumference was observed after 12 weeks of semaglutide therapy. By 24 weeks, a sustained reduction in these indicators continued. After 6 months of semaglutide use, positive changes in the lipid profile were identified: a decrease in total cholesterol by 8.27% due to a decrease in non-HDL cholesterol, LDL cholesterol by 12.73 %, triglycerides by 13.09 %, and the atherogenic index by 1.83 %. Velgia® therapy for 6 months led to a reduction in the calculated 10-year cardiovascular risk according to the SCORE2 scale by 18.6 %. Analysis of anthropometric and biochemical blood data showed a significant decrease in indicators, indicating a reduced risk of cardiovascular events in patients with obesity. Conclusion. During semaglutide therapy, no clinically significant changes were observed in liver function parameters (ALT, AST, ALP, bilirubin), pancreas (amylase), kidneys (creatinine, urea, GFR), and systemic inflammation markers (CRP). However, a significant decrease in transaminase activity (ALT, AST) and blood uric acid concentration was noted. The registered adverse events (primarily gastrointestinal: nausea, epigastric discomfort) were temporary and moderate in nature. No cardiovascular events were observed during the use of semaglutide.
- 18 June 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (3)
Therapeutic options for urogenital herpes and chlamydia using a double-stranded RNA sodium salt (lyophilisate): Results of the All-Russian Observational Program INTEGRA
The aim. To evaluate the efficacy and safety of the double-stranded RNA sodium salt drug RADAMIN®VIRO (lyophilisate) in everyday practice with men and women having genital herpes and/or chronic urogenital chlamydial infection. Materials and methods . A multicenter observational non-randomized clinical trial was performed. The study included records of 2 714 patients: 488 patients suffering from chlamydia or a combined infection, 2 226 individuals with a confirmed diagnosis of herpes infection, of both sexes, aged over 18 years, who met the inclusion/exclusion criteria and for whom the attending physician prescribed a course of treatment with RADAMIN®VIRO as part of complex therapy prior to inclusion in this study. The efficacy of the drug was assessed during the course of treatment (as part of complex therapy for genital herpes/chronic urogenital chlamydial infection) in relation to: dynamics of symptoms (objective and subjective); speed of regression of clinical manifestations of the infection; frequency of relapses during the observation period; duration of the inter-relapse period; dynamics of quality of life according to the “Dermatological Quality of Life Index” questionnaire; and the safety of the drug was assessed. Results . It was shown that as early as day 14 of observation (visit B2), the proportion of patients with low severity or absence of subjective symptoms characteristic of chlamydial, herpetic, or combined infection increased to an average level of 86.62–91.65 %; the proportion of patients with the absence of objective symptoms characteristic of chlamydial, herpetic, or combined infection increased to an average level of 87.09–99.69 %. It was shown that by day 7 of observation, the severity of subjective symptoms decreased from 1.27–1.72 to 0.39–0.55 in group A56 (chlamydia or combined infection), and in group A60 (herpes), it also decreased from 1.45–1.63 to an average level of 1.21–1.30; by day 14 of observation — in 32.9 % of patients, by day 90 of observation — in 1.2 % of patients, by day 180 of the study — in 0.7 % of patients. Thus, recovery occurred within 3 months from the start of therapy and observation in 99.3 % of patients — all study participants ( p < 0.001). Conclusion. Based on the obtained data, a conclusion can be drawn regarding the efficacy, safety, and appropriateness of including RADAMIN®VIRO in the complex therapy for patients with genital herpes and urogenital chlamydial infection.
- 18 June 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (3)
Therapeutic options for urogenital herpes and chlamydia using a double-stranded RNA sodium salt (lyophilisate): Results of the All-Russian Observational Program INTEGRA
The aim. To evaluate the efficacy and safety of the double-stranded RNA sodium salt drug RADAMIN®VIRO (lyophilisate) in everyday practice with men and women having genital herpes and/or chronic urogenital chlamydial infection. Materials and methods . A multicenter observational non-randomized clinical trial was performed. The study included records of 2 714 patients: 488 patients suffering from chlamydia or a combined infection, 2 226 individuals with a confirmed diagnosis of herpes infection, of both sexes, aged over 18 years, who met the inclusion/exclusion criteria and for whom the attending physician prescribed a course of treatment with RADAMIN®VIRO as part of complex therapy prior to inclusion in this study. The efficacy of the drug was assessed during the course of treatment (as part of complex therapy for genital herpes/chronic urogenital chlamydial infection) in relation to: dynamics of symptoms (objective and subjective); speed of regression of clinical manifestations of the infection; frequency of relapses during the observation period; duration of the inter-relapse period; dynamics of quality of life according to the “Dermatological Quality of Life Index” questionnaire; and the safety of the drug was assessed. Results . It was shown that as early as day 14 of observation (visit B2), the proportion of patients with low severity or absence of subjective symptoms characteristic of chlamydial, herpetic, or combined infection increased to an average level of 86.62–91.65 %; the proportion of patients with the absence of objective symptoms characteristic of chlamydial, herpetic, or combined infection increased to an average level of 87.09–99.69 %. It was shown that by day 7 of observation, the severity of subjective symptoms decreased from 1.27–1.72 to 0.39–0.55 in group A56 (chlamydia or combined infection), and in group A60 (herpes), it also decreased from 1.45–1.63 to an average level of 1.21–1.30; by day 14 of observation — in 32.9 % of patients, by day 90 of observation — in 1.2 % of patients, by day 180 of the study — in 0.7 % of patients. Thus, recovery occurred within 3 months from the start of therapy and observation in 99.3 % of patients — all study participants ( p < 0.001). Conclusion. Based on the obtained data, a conclusion can be drawn regarding the efficacy, safety, and appropriateness of including RADAMIN®VIRO in the complex therapy for patients with genital herpes and urogenital chlamydial infection.
- Open Access
- 17 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 637
Efficacy and Safety of Tegoprazan in Helicobacter pylori Eradication: An Umbrella Review of Meta-Analyses
Objective: This umbrella review synthesizes and critically appraises the evidence on the efficacy and safety of tegoprazan-based versus proton pump inhibitor (PPI)-based regimens for Helicobacter pylori (H. pylori) eradication. Methods: This umbrella review was pre-registered in PROSPERO (CRD420251271120). Systematic reviews and meta-analyses published between 1 January 2018 and 10 December 2025 were identified through MEDLINE/PubMed, EMBASE, and the Cochrane Library. Reviews comparing tegoprazan-based and PPI-based eradication regimens in adult patients were included. Methodological quality was assessed using AMSTAR-2, risk of bias with ROBIS, and certainty of evidence with GRADE. Pooled relative risks (RRs) were calculated, with subgroup analyses by study design, treatment duration, and therapeutic regimen. Results: Eight systematic reviews and meta-analyses encompassing 17 primary studies and 12,714 participants were included. Tegoprazan-based regimens were associated with a statistically significant improvement in eradication efficacy compared with PPI-based therapies (RR = 1.019; 95% CI: 1.003–1.035; p = 0.021). In randomized controlled trials, the benefit was more pronounced (RR = 1.037; 95% CI: 1.015–1.061; p = 0.001), whereas no statistically significant benefit was observed in non-randomized studies (RR = 1.014; 95% CI: 0.991–1.037; p = 0.235). The efficacy advantage was mainly confined to quadruple therapy regimens (RR = 1.044; 95% CI: 1.002–1.088; p = 0.038). Tegoprazan-based regimens were associated with a lower incidence of overall adverse events compared with the PPI group (RR = 0.930; 95% CI: 0.885–0.976; p = 0.003). Conclusions: Tegoprazan-containing regimens were associated with a modest but statistically significant improvement in H. pylori eradication compared with PPI-containing regimens, particularly in randomized controlled trials and quadruple therapy regimens.
- 17 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 637
Open AccessEfficacy and Safety of Tegoprazan in Helicobacter pylori Eradication: An Umbrella Review of Meta-Analyses
Objective: This umbrella review synthesizes and critically appraises the evidence on the efficacy and safety of tegoprazan-based versus proton pump inhibitor (PPI)-based regimens for Helicobacter pylori (H. pylori) eradication. Methods: This umbrella review was pre-registered in PROSPERO (CRD420251271120). Systematic reviews and meta-analyses published between 1 January 2018 and 10 December 2025 were identified through MEDLINE/PubMed, EMBASE, and the Cochrane Library. Reviews comparing tegoprazan-based and PPI-based eradication regimens in adult patients were included. Methodological quality was assessed using AMSTAR-2, risk of bias with ROBIS, and certainty of evidence with GRADE. Pooled relative risks (RRs) were calculated, with subgroup analyses by study design, treatment duration, and therapeutic regimen. Results: Eight systematic reviews and meta-analyses encompassing 17 primary studies and 12,714 participants were included. Tegoprazan-based regimens were associated with a statistically significant improvement in eradication efficacy compared with PPI-based therapies (RR = 1.019; 95% CI: 1.003–1.035; p = 0.021). In randomized controlled trials, the benefit was more pronounced (RR = 1.037; 95% CI: 1.015–1.061; p = 0.001), whereas no statistically significant benefit was observed in non-randomized studies (RR = 1.014; 95% CI: 0.991–1.037; p = 0.235). The efficacy advantage was mainly confined to quadruple therapy regimens (RR = 1.044; 95% CI: 1.002–1.088; p = 0.038). Tegoprazan-based regimens were associated with a lower incidence of overall adverse events compared with the PPI group (RR = 0.930; 95% CI: 0.885–0.976; p = 0.003). Conclusions: Tegoprazan-containing regimens were associated with a modest but statistically significant improvement in H. pylori eradication compared with PPI-containing regimens, particularly in randomized controlled trials and quadruple therapy regimens.
- Open Access
- 22 March 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (1) , 109-132
Comparative study of the efficacy and safety of tirzepatide drugs in metabolic syndrome
In the last decade, developed countries have seen a steady increase in the prevalence of metabolic disorders. The most significant among them are obesity and type 2 diabetes mellitus. Tirzepatide is an innovative drug, representing the first-in-class dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Tirzepatide combines the action of two key incretin hormones, providing more comprehensive and effective regulation of glycemia and metabolism compared to traditional GLP-1 monoagonists. Tirzepatide was unavailable in Russia for a long time. However, in 2025, the first domestically produced tirzepatide drug, Tirzetta® (LLC “PROMMOMED RUS”), appeared. The aim. To conduct a comparative evaluation of the efficacy and safety of the reproduced drug Tirzetta® (INN: Tirzepatide, manufacturer LLC “PROMMOMED RUS”) and the reference drug Mounjaro® (INN: Tirzepatide, manufacturer “Eli Lilly”) in a mouse model with induced metabolic syndrome (MS). Materials and methods. The study was conducted on male mice of the C57BL/6 line. To metabolic syndrome (MS) was induced in animals with a diet high in fat and carbohydrates. Three batches of Tirzetta® and one series of Munjaro® were investigated. The drugs were administered at a dosage of 150 µg/kg subcutaneously once every three days for 15 days. During the experiment, glucose tolerance and insulin sensitivity tests were performed. The type of metabolism was determined by indirect calorimetry data. Mice were euthanized on 25th day for humane reasons upon reaching any of the following criteria: body weight loss of more than 15% in a week; serious injuries (fractures, amputations, etc.), appearance of non-healing wounds; seizures; unconscious state. A complete blood count was performed, and the following parameters were determined: glucose, triglycerides, cholesterol, AST, ALT. Necropsy was performed after euthanasia. During necropsy, the thoracic and abdominal organs of the animals were examined, and organs were dissected and weighed. Results. In the MS group animals, body weight increased to 39.5 ± 0.6 g compared to the control group (31.9 ± 0.6 g), representing a 24% increase. Significant hyperglycemia was recorded with a glucose concentration of 14.9 ± 2.7 mmol/L versus 6.1 ± 0.4 mmol/L in the control, as well as a pronounced decrease in glucose tolerance in the loading test. The investigated tirzepatide drugs demonstrated a pronounced hypophagic effect with a 26–28% reduction in body weight, normalization of glycemia with a 48–53% decrease in glucose concentration, and improvement in glucose tolerance and insulin sensitivity. Indirect calorimetry data indicated a decrease in the respiratory exchange ratio, suggesting lipolysis activation. A significant reduction in triglyceride content in blood serum and liver was revealed. The bioequivalence of the investigated drugs Tirzetta® and Mounjaro® was established in the experimental MS model in mice based on a set of therapeutic efficacy and safety indicators. Conclusion . Studies on an experimental model of induced MS in mice showed equivalent efficacy of Tirzetta® (INN: Tirzepatide, manufacturer LLC “PROMMOMED RUS”, Russia) and Mounjaro® (INN: Tirzepatide, manufacturer “Eli Lilly”, USA).
- 22 March 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (1) , 109-132
Open AccessComparative study of the efficacy and safety of tirzepatide drugs in metabolic syndrome
In the last decade, developed countries have seen a steady increase in the prevalence of metabolic disorders. The most significant among them are obesity and type 2 diabetes mellitus. Tirzepatide is an innovative drug, representing the first-in-class dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Tirzepatide combines the action of two key incretin hormones, providing more comprehensive and effective regulation of glycemia and metabolism compared to traditional GLP-1 monoagonists. Tirzepatide was unavailable in Russia for a long time. However, in 2025, the first domestically produced tirzepatide drug, Tirzetta® (LLC “PROMMOMED RUS”), appeared. The aim. To conduct a comparative evaluation of the efficacy and safety of the reproduced drug Tirzetta® (INN: Tirzepatide, manufacturer LLC “PROMMOMED RUS”) and the reference drug Mounjaro® (INN: Tirzepatide, manufacturer “Eli Lilly”) in a mouse model with induced metabolic syndrome (MS). Materials and methods. The study was conducted on male mice of the C57BL/6 line. To metabolic syndrome (MS) was induced in animals with a diet high in fat and carbohydrates. Three batches of Tirzetta® and one series of Munjaro® were investigated. The drugs were administered at a dosage of 150 µg/kg subcutaneously once every three days for 15 days. During the experiment, glucose tolerance and insulin sensitivity tests were performed. The type of metabolism was determined by indirect calorimetry data. Mice were euthanized on 25th day for humane reasons upon reaching any of the following criteria: body weight loss of more than 15% in a week; serious injuries (fractures, amputations, etc.), appearance of non-healing wounds; seizures; unconscious state. A complete blood count was performed, and the following parameters were determined: glucose, triglycerides, cholesterol, AST, ALT. Necropsy was performed after euthanasia. During necropsy, the thoracic and abdominal organs of the animals were examined, and organs were dissected and weighed. Results. In the MS group animals, body weight increased to 39.5 ± 0.6 g compared to the control group (31.9 ± 0.6 g), representing a 24% increase. Significant hyperglycemia was recorded with a glucose concentration of 14.9 ± 2.7 mmol/L versus 6.1 ± 0.4 mmol/L in the control, as well as a pronounced decrease in glucose tolerance in the loading test. The investigated tirzepatide drugs demonstrated a pronounced hypophagic effect with a 26–28% reduction in body weight, normalization of glycemia with a 48–53% decrease in glucose concentration, and improvement in glucose tolerance and insulin sensitivity. Indirect calorimetry data indicated a decrease in the respiratory exchange ratio, suggesting lipolysis activation. A significant reduction in triglyceride content in blood serum and liver was revealed. The bioequivalence of the investigated drugs Tirzetta® and Mounjaro® was established in the experimental MS model in mice based on a set of therapeutic efficacy and safety indicators. Conclusion . Studies on an experimental model of induced MS in mice showed equivalent efficacy of Tirzetta® (INN: Tirzepatide, manufacturer LLC “PROMMOMED RUS”, Russia) and Mounjaro® (INN: Tirzepatide, manufacturer “Eli Lilly”, USA).
- Top Cited PapersOpen Access
- 14 January 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 144
Rebamipide as an Adjunctive Therapy for Gastrointestinal Diseases: An Umbrella Review
Objective: This umbrella review aimed to synthesize evidence from meta-analyses on the efficacy of rebamipide in major gastrointestinal disorders and dyspeptic symptoms. Methods: This umbrella review followed Joanna Briggs Institute standards and was registered in PROSPERO (CRD420251185686). A comprehensive search of MEDLINE, EMBASE, Cochrane, and Scopus (1 January 1985, to 10 September 2025) was conducted to identify systematic reviews and meta-analyses assessing rebamipide therapy. Methodological quality was appraised using AMSTAR-2, ROBIS, and GRADE tools. Pooled data were analyzed using fixed- or random-effects models according to heterogeneity, as assessed using the I2 statistic. Results: Eleven meta-analyses (88 primary studies) were included. Rebamipide significantly improved H. pylori eradication (OR = 1.76; 95% CI: 1.44–2.16), reduced NSAID-induced mucosal injury (OR = 2.72; 95% CI: 1.89–5.14), enhanced ulcer healing after endoscopic submucosal dissection (OR = 2.28; 95% CI: 1.42–3.65), and alleviated dyspeptic symptoms (OR = 2.95; 95% CI: 1.04–8.37). Overall evidence quality was moderate to high, with low to moderate risk of bias. Conclusions: Rebamipide demonstrates consistent therapeutic benefits across diverse gastrointestinal disorders, improving H. pylori eradication rates, mucosal protection, ulcer healing, and symptom relief. These findings support rebamipide as an effective and well-tolerated adjunctive agent for the prevention and management of upper gastrointestinal diseases.
- 14 January 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 144
Top Cited PapersOpen AccessRebamipide as an Adjunctive Therapy for Gastrointestinal Diseases: An Umbrella Review
Objective: This umbrella review aimed to synthesize evidence from meta-analyses on the efficacy of rebamipide in major gastrointestinal disorders and dyspeptic symptoms. Methods: This umbrella review followed Joanna Briggs Institute standards and was registered in PROSPERO (CRD420251185686). A comprehensive search of MEDLINE, EMBASE, Cochrane, and Scopus (1 January 1985, to 10 September 2025) was conducted to identify systematic reviews and meta-analyses assessing rebamipide therapy. Methodological quality was appraised using AMSTAR-2, ROBIS, and GRADE tools. Pooled data were analyzed using fixed- or random-effects models according to heterogeneity, as assessed using the I2 statistic. Results: Eleven meta-analyses (88 primary studies) were included. Rebamipide significantly improved H. pylori eradication (OR = 1.76; 95% CI: 1.44–2.16), reduced NSAID-induced mucosal injury (OR = 2.72; 95% CI: 1.89–5.14), enhanced ulcer healing after endoscopic submucosal dissection (OR = 2.28; 95% CI: 1.42–3.65), and alleviated dyspeptic symptoms (OR = 2.95; 95% CI: 1.04–8.37). Overall evidence quality was moderate to high, with low to moderate risk of bias. Conclusions: Rebamipide demonstrates consistent therapeutic benefits across diverse gastrointestinal disorders, improving H. pylori eradication rates, mucosal protection, ulcer healing, and symptom relief. These findings support rebamipide as an effective and well-tolerated adjunctive agent for the prevention and management of upper gastrointestinal diseases.
- Open Access
- 30 September 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (10) , 458
Tailored Therapy vs. Empirical Therapy for Helicobacter pylori Eradication: An Umbrella Review of Systematic Reviews and Meta-Analyses
Objective: This study aimed to provide the first umbrella review to systematically evaluate the evidence for the efficacy of personalized susceptibility-guided tailored therapy (TT) versus empirical therapy (ET) for Helicobacter pylori eradication. Methods: An umbrella review was conducted following Joanna Briggs Institute standards, registered in PROSPERO (CRD420251104335). A comprehensive literature search across MEDLINE/PubMed, EMBASE, RSCI, and Google Scholar identified systematic reviews and meta-analyses published between 1 January 1985 and 10 June 2025. Studies comparing TT and ET were included. Methodological quality was assessed using a modified AMSTAR-2 tool, GRADE, and the risk of bias was evaluated using the ROBIS tool. Data were synthesized using a random-effects model, with heterogeneity assessed using the I2 statistic. Results: A total of 7 systematic reviews and meta-analyses were included, covering 66 primary studies. TT was associated with a significantly higher eradication rate compared to ET (RR = 1.265; 95% CI: 1.137–1.407). In first-line treatment, TT showed consistent superiority (RR = 1.156; 95% CI: 1.117–1.196), which was further supported by high-quality meta-analyses (RR = 1.288; 95% CI: 1.022–1.624). The benefit in second-line therapy did not reach statistical significance (RR = 1.291; 95% CI: 0.834–1.999). The absolute eradication rates were 84.31% (95% CI: 80.94–87.41) for TT and 67.80% (95% CI: 58.48–76.46) for ET. Conclusions: TT is more effective than ET in the first-line H. pylori eradication regimen. However, the benefit is less evident in second-line regimens.
- 30 September 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (10) , 458
Open AccessTailored Therapy vs. Empirical Therapy for Helicobacter pylori Eradication: An Umbrella Review of Systematic Reviews and Meta-Analyses
Objective: This study aimed to provide the first umbrella review to systematically evaluate the evidence for the efficacy of personalized susceptibility-guided tailored therapy (TT) versus empirical therapy (ET) for Helicobacter pylori eradication. Methods: An umbrella review was conducted following Joanna Briggs Institute standards, registered in PROSPERO (CRD420251104335). A comprehensive literature search across MEDLINE/PubMed, EMBASE, RSCI, and Google Scholar identified systematic reviews and meta-analyses published between 1 January 1985 and 10 June 2025. Studies comparing TT and ET were included. Methodological quality was assessed using a modified AMSTAR-2 tool, GRADE, and the risk of bias was evaluated using the ROBIS tool. Data were synthesized using a random-effects model, with heterogeneity assessed using the I2 statistic. Results: A total of 7 systematic reviews and meta-analyses were included, covering 66 primary studies. TT was associated with a significantly higher eradication rate compared to ET (RR = 1.265; 95% CI: 1.137–1.407). In first-line treatment, TT showed consistent superiority (RR = 1.156; 95% CI: 1.117–1.196), which was further supported by high-quality meta-analyses (RR = 1.288; 95% CI: 1.022–1.624). The benefit in second-line therapy did not reach statistical significance (RR = 1.291; 95% CI: 0.834–1.999). The absolute eradication rates were 84.31% (95% CI: 80.94–87.41) for TT and 67.80% (95% CI: 58.48–76.46) for ET. Conclusions: TT is more effective than ET in the first-line H. pylori eradication regimen. However, the benefit is less evident in second-line regimens.
- Open Access
- 29 September 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (5) , 338-349
Prospects for the use of an original medicine based on hexapeptide succinate for organ protection in various diseases
The aim. To analyze and summarize the available results of experimental and clinical scientific studies of synthetic analogs of leu-enkephalin; to evaluate the expansion of the spectrum of application of the original medicine based on hexapeptide succinate in patients with various diseases of different etiologies.Materials and methods. An analysis of scientific literature data in the PubMed, eLibrary.ru and CyberLeninka databases was carried out. The search depth was 50 years (from 1976 to 2024), the list of references includes 60 scientific papers.Results. It was revealed that receptors for endogenous opioid peptides are widespread in living organisms. Modern neuropharmacology recognizes 4 main types of opioid receptors: μ (MOR) — mu, δ (DOR) — delta, κ (KOR) — kappa and NOP — nociceptive receptor, which bind to endogenous opioids such as enkephalins, endorphins, endomorphins, dynorphins and nociceptin. Due to their antioxidant, immunomodulatory, and anti-inflammatory properties, analogs of opioid peptides are widely used in Russian medicine. A number of experimental and clinical studies are presented, to prove that agonists of delta-opioid receptors can “soften” organ damage in a variety of diseases accompanied by oxidative stress and endothelial dysfunction. The dose-dependent regulatory effect is realized with intravenous, intramuscular and intranasal administration. The therapeutic efficacy of leu-enkephalin analogs based on tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine is analyzed, and the prospects for using the new original Russian medicine Ambervin® Pulmo with the inclusion of succinic acid salts are also discussed.Conclusion. The information on the functional properties of leucine-enkephalin analogs presented in the article indicates broad prospects for the use of medicines based on tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine with the inclusion of succinic acid salt in the complex therapy of many diseases for the purpose of organ protection.
- 29 September 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (5) , 338-349
Open AccessProspects for the use of an original medicine based on hexapeptide succinate for organ protection in various diseases
The aim. To analyze and summarize the available results of experimental and clinical scientific studies of synthetic analogs of leu-enkephalin; to evaluate the expansion of the spectrum of application of the original medicine based on hexapeptide succinate in patients with various diseases of different etiologies.Materials and methods. An analysis of scientific literature data in the PubMed, eLibrary.ru and CyberLeninka databases was carried out. The search depth was 50 years (from 1976 to 2024), the list of references includes 60 scientific papers.Results. It was revealed that receptors for endogenous opioid peptides are widespread in living organisms. Modern neuropharmacology recognizes 4 main types of opioid receptors: μ (MOR) — mu, δ (DOR) — delta, κ (KOR) — kappa and NOP — nociceptive receptor, which bind to endogenous opioids such as enkephalins, endorphins, endomorphins, dynorphins and nociceptin. Due to their antioxidant, immunomodulatory, and anti-inflammatory properties, analogs of opioid peptides are widely used in Russian medicine. A number of experimental and clinical studies are presented, to prove that agonists of delta-opioid receptors can “soften” organ damage in a variety of diseases accompanied by oxidative stress and endothelial dysfunction. The dose-dependent regulatory effect is realized with intravenous, intramuscular and intranasal administration. The therapeutic efficacy of leu-enkephalin analogs based on tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine is analyzed, and the prospects for using the new original Russian medicine Ambervin® Pulmo with the inclusion of succinic acid salts are also discussed.Conclusion. The information on the functional properties of leucine-enkephalin analogs presented in the article indicates broad prospects for the use of medicines based on tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine with the inclusion of succinic acid salt in the complex therapy of many diseases for the purpose of organ protection.
- Open Access
- 4 September 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (4) , 297-315
Molnupiravir in the treatment of patients with influenza or acute respiratory viral infections: a multicenter comparative randomized double-blind placebo-controlled trial
The aim. To evaluate the efficacy and safety of molnupiravir compared to placebo in patients with influenza and/or ARVI.Materials and methods. The study involved 300 patients. The study included patients aged 18 to 80 years with clinical signs of influenza/ARVI (duration no more than 48 hours): elevated body temperature ≥37.5℃ and the presence of at least 2 symptoms of moderate severity (chills, headache, myalgia, sore throat, nasal congestion, runny nose, sneezing, cough, with laboratory-confirmed diagnosis of influenza/ARVI at the time of screening), meeting the selection criteria for the study. Group 1 (n=150) received the investigational medicine molnupiravir (Esperavir®, Promomed Rus LLC, Russia) 800 mg (4 capsules) 2 times/day (daily dose 1600 mg) for 5 days; Group 2 (n=150) received placebo 4 capsules 2 times/day for 5 days, then patient observation was carried out until day 14 (4 visits after screening). The effectiveness of therapy was assessed according to primary and secondary efficacy criteria. The primary efficacy criterion was the time (in days) to clinical recovery. Safety was assessed by considering the number and severity of adverse events (AEs) and serious adverse events (SAEs). For the analysis of qualitative indicators, an intergroup comparison of proportions was performed using a two-sided version of Fisher's exact test, or the χ2 ("chi-square") test. For quantitative indicators — using the non-parametric Mann-Whitney test. Differences were considered statistically significant at p Results. According to the results of the assessment of the primary efficacy criterion, it was shown that molnupiravir therapy statistically significantly reduces the time to clinical recovery compared with placebo (p=0.000039). According to secondary efficacy criteria, a statistically significant advantage of therapy with the investigational medicine compared with placebo was also demonstrated in terms of the frequency of patients who achieved clinical recovery at Visits 2 and 3 p=0.0110, p=0.0070), the frequency of virus elimination. Even on the 3rd day of therapy, the frequency of virus elimination in the investigational drug group was 64.7% compared with 40% in the placebo group (ppConclusion. As a result of the phase III clinical study, the efficacy of molnupiravir (Esperavir®, Promomed Rus LLC, Russia) in the treatment of influenza and/or ARVI and the prevention of the risk of developing complications compared with placebo was proven: patients achieved clinical recovery as early as on the 3rd day of therapy. A favorable safety profile was shown, corresponding to the general characteristics of the medicine.
- 4 September 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (4) , 297-315
Open AccessMolnupiravir in the treatment of patients with influenza or acute respiratory viral infections: a multicenter comparative randomized double-blind placebo-controlled trial
The aim. To evaluate the efficacy and safety of molnupiravir compared to placebo in patients with influenza and/or ARVI.Materials and methods. The study involved 300 patients. The study included patients aged 18 to 80 years with clinical signs of influenza/ARVI (duration no more than 48 hours): elevated body temperature ≥37.5℃ and the presence of at least 2 symptoms of moderate severity (chills, headache, myalgia, sore throat, nasal congestion, runny nose, sneezing, cough, with laboratory-confirmed diagnosis of influenza/ARVI at the time of screening), meeting the selection criteria for the study. Group 1 (n=150) received the investigational medicine molnupiravir (Esperavir®, Promomed Rus LLC, Russia) 800 mg (4 capsules) 2 times/day (daily dose 1600 mg) for 5 days; Group 2 (n=150) received placebo 4 capsules 2 times/day for 5 days, then patient observation was carried out until day 14 (4 visits after screening). The effectiveness of therapy was assessed according to primary and secondary efficacy criteria. The primary efficacy criterion was the time (in days) to clinical recovery. Safety was assessed by considering the number and severity of adverse events (AEs) and serious adverse events (SAEs). For the analysis of qualitative indicators, an intergroup comparison of proportions was performed using a two-sided version of Fisher's exact test, or the χ2 ("chi-square") test. For quantitative indicators — using the non-parametric Mann-Whitney test. Differences were considered statistically significant at p Results. According to the results of the assessment of the primary efficacy criterion, it was shown that molnupiravir therapy statistically significantly reduces the time to clinical recovery compared with placebo (p=0.000039). According to secondary efficacy criteria, a statistically significant advantage of therapy with the investigational medicine compared with placebo was also demonstrated in terms of the frequency of patients who achieved clinical recovery at Visits 2 and 3 p=0.0110, p=0.0070), the frequency of virus elimination. Even on the 3rd day of therapy, the frequency of virus elimination in the investigational drug group was 64.7% compared with 40% in the placebo group (ppConclusion. As a result of the phase III clinical study, the efficacy of molnupiravir (Esperavir®, Promomed Rus LLC, Russia) in the treatment of influenza and/or ARVI and the prevention of the risk of developing complications compared with placebo was proven: patients achieved clinical recovery as early as on the 3rd day of therapy. A favorable safety profile was shown, corresponding to the general characteristics of the medicine.